Navigation Links
Adeona Announces Initiation of Phase II Clinical Trial of Trimesta™ for Cognitive Dysfunction in Multiple Sclerosis
Date:1/19/2012

sta™ therapy (p = 0.04).[i] The PASAT is a measure of cognitive function that assesses auditory information processing speed and flexibility, as well as calculation ability and is widely used in MS to measure cognitive function. Estriol has also been shown to have neuroprotective benefits in animal models of MS, a property not generally shared by currently approved MS therapies.[ii]

The new Phase II clinical trial is a randomized, double-blind, placebo-controlled trial intended to enroll 64 relapsing-remitting or secondary-progressive female MS patients. Subjects will be equally randomized to receive either once-daily Trimesta™ (oral estriol) or matching placebo. The primary outcome measure is the average change in PASAT scores at 12 months between each group. Secondary outcome measures include relapse rates (the primary endpoint of the ongoing Phase II clinical trial of Trimesta™ for relapsing-remitting MS), whole brain atrophy determined by MRI and safety. Charitable organizations have pledged to financially support a majority of the new MS clinical trial. Detailed information regarding this clinical trial, including contact information for the clinical site, is available at http://www.clinicaltrials.gov/ct2/show/NCT01466114.

In addition to the clinical trial of Trimesta for cognitive dysfunction in MS, Trimesta™ is also the subject of a separate ongoing 15-center Phase II, randomized, double-blind, placebo-controlled clinical trial seeking to demonstrate Trimesta's ability to reduce relapse rates in women with the relapsing-remitting form of MS. With over $8 million in grant funding awarded to date, this separate ongoing Trimesta™ clinical trial should be funded to its completion. Additional information regarding the relapsing-remitting multiple sclerosis clinical trial is available at http://www
'/>"/>

SOURCE Adeona Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Adeona Appoints Julie A. Caudill, B.B.A., Vice President of Finance and Corporate Controller
2. Adeonas Multiple Sclerosis Clinical Trial Receives $1,594,553 Grant
3. Adeona Announces Positive Alzheimers Subgroup Analysis that Supports Additional Clinical Study of Proprietary Zinc-Based Therapy
4. Adeona CEO to Present at the NYC Medtech Forum
5. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
6. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
7. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
8. Anesiva Announces Second Quarter 2008 Financial Results and Update
9. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
10. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
11. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... -- Sapphire Energy, Inc. , a global leader ... biotechnology veteran James Levine as president, CEO ... Cynthia ,CJ, Warner, who is stepping down from her ... company,s board of directors. "The impact of ... scale algae-based fuels has been tremendous, from overseeing the ...
(Date:7/28/2014)... Research and Markets has announced the addition ... report to their offering. ... the designing and engineering of completely new biological parts, ... natural biological systems that provide improved and desirable functions. ... genetic engineering because it not only alters existing metabolic ...
(Date:7/28/2014)... MADISON, Wis. , July 28, 2014   ... chronic respiratory disease, announced the hire of Brad ... Development. Towle will be responsible for driving the company,s ... "Brad,s broad experience in healthcare, and specifically his past ... valuable insight to the company at this pivotal time ...
(Date:7/28/2014)... COLLEGE STATION, Texas , July 28, 2014   The ... be a 177-key, 4-star boutique hotel in the heart of The ... Texas.  Photo - http://photos.prnewswire.com/prnh/20140725/130455 ... hotel within ATLAS , The ... standard rooms and suites, a sleek restaurant and bar, a wellness ...
Breaking Biology Technology:Sapphire Energy Announces New CEO James Levine 2Sapphire Energy Announces New CEO James Levine 3Global Synthetic Biology Market 2014-2018 2Propeller Health Hires Brad Towle as Senior Vice President of Business and Client Development 2Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 2Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 3Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 4
... 31 Revotar,Biopharmaceuticals AG., today announced first positive ... pilot study in 14 patients with,stable COPD stage ... of Bimosiamose,twice a day. The study was conducted ... Witt and the Respiratory Institute Wiesbaden, Dr.,Beeh. The ...
... Oct. 31 Amedica Corporation,an orthopedic implants company ... the U.S. Food and Drug Administration,has granted 510(k) ... The Valeo(TM) Cervical Plate system combines features aimed ... The,Valeo(TM) Cervical Plate system is intended for anterior ...
... Md., Oct. 31 Micromet, Inc.,(Nasdaq: MITI ... of,novel, proprietary antibody-based products for cancer, inflammation and,autoimmune ... and,Chief Executive Officer of Micromet, will present at ... Conference in New York, on,Wednesday, November 7, 2007 ...
Cached Biology Technology:Revotar Reports First Positive Clinical Results From Phase IIa Study in COPD 2Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 2007 2
(Date:7/28/2014)... Medicine have pinpointed a mechanism in part of the brain ... linking it to both type 1 and type 2 diabetes. ... Proceedings of the National Academies of Sciences . ... in a part of the hypothalamus known as the ventromedial ... control glucose levels in the blood," said lead author Sabrina ...
(Date:7/28/2014)... , a wild relative of the domestic tomato, has ... the labs headed by Professors Neelima Sinha and Julin ... The new genome information may help breeders produce tastier, ... in the journal Nature Genetics , was lead ... Germany. The UC Davis labs carried out work on ...
(Date:7/28/2014)... Alzheimer,s disease and other forms of dementia, but the ... , University of Washington bioengineers have a designed a ... the body,s normal proteins into a state that,s linked ... Type 2 diabetes and Lou Gehrig,s disease. The synthetic ... normal state into an abnormally folded form by targeting ...
Breaking Biology News(10 mins):Glucose 'control switch' in the brain key to both types of diabetes 2New protein structure could help treat Alzheimer's, related diseases 2New protein structure could help treat Alzheimer's, related diseases 3
... two metabolic enzymes, isocitrate dehydrogenase-1 and 2 (IDH1 and IDH2), ... myeloid leukemias (AML). As a result, mutant IDH proteins have ... of adult leukemia. Now a scientific team at Beth ... mouse model of the most common IDH2 mutation in human ...
... the latest in the ocean sciences at the 2014 ... Hotel information, U.S. visa regulations for international reporters ... sciences at the 2014 Ocean Sciences Meeting , ... research findings about the world,s ,oceans at the Ocean ...
... early life experiences may affect food choices in adulthood will ... which includes researchers from the Sahlgrenska Academy. The 7.4 ... out what drives decisions of when we eat and the ... the University of Edinburgh, will examine how eating habits develop ...
Cached Biology News:Animal model demonstrates role for metabolic enzyme in acute myeloid leukemia 2Animal model demonstrates role for metabolic enzyme in acute myeloid leukemia 32014 Ocean Sciences Meeting: Discover the latest in oceanography; press registration open 22014 Ocean Sciences Meeting: Discover the latest in oceanography; press registration open 32014 Ocean Sciences Meeting: Discover the latest in oceanography; press registration open 480 million SEK study seeks to explain what drives our appetites 2
Rabbit polyclonal to Lck (phospho Y192) ( Abpromise for all tested applications). entrezGeneID: 3932 SwissProtID: P06239...
...
Rabbit polyclonal to LCAT ( Abpromise for all tested applications). entrezGeneID: 3931 SwissProtID: P04180...
HAMP Immunogen: HAMP (AAH20612, 25 a.a. ~ 85 a.a) full length recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: